Cuppone et al. Journal of Experimental & Clinical Cancer Research 2011, 30:54 http://www.jeccr.com/content/30/1/54 Page 8 of 9 Competing interests The authors declare that they have no competing interests. Received: 7 March 2011 Accepted: 12 May 2011 Published: 12 May 2011 References 1. Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics. CA: a cancer journal for clinicians 2010. 2. Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, Vahdat LT, Obel J, Vogelzang N, Markman M, et al: Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening–a report from the American Society of Clinical Oncology. J Clin Oncol 2009, 27(35):6052-6069. 3. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M: Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v15-19. 4. Andreetta C, Minisini AM, Miscoria M, Puglisi F: First-line chemotherapy with or without biologic agents for metastatic breast cancer. Crit Rev Oncol Hematol 76(2):99-111. 5. Andreopoulou E, Hortobagyi GN: Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol 2008, 26(22):3660-3662. 6. Guarneri V, Conte P: Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. The oncologist 2009, 14(7):645-656. 7. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5):1011-1027. 8. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, et al: Association between HER- 2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004, 10(5):1706-1716. 9. Sledge GW Jr: Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002, 29(3 Suppl 11):104-110. 10. de Castro Junior G, Puglisi F, de Azambuja E, El Saghir NS, Awada A: Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the “do ut des” paradigm). Crit Rev Oncol Hematol 2006, 59(1):40-50. 11. Jain RK: Clearing the smoke on nicotine and angiogenesis. Nat Med 2001, 7(7):775-777. 12. Gasparini G, Longo R, Fanelli M, Teicher BA: Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005, 23(6):1295-1311. 13. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL: Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009, 27(30):4966-4972. 14. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, et al: Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 2011. 15. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. The New England journal of medicine 2007, 357(26):2666-2676. 16. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez E, Yardley D, Zhou X, Phan S: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 2009, 27(15S):1005. 17. Pignon JP, Hill C: Meta-analyses of randomised clinical trials in oncology. The lancet oncology 2001, 2(8):475-482. 18. Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nistico C, Terzoli E, Cognetti F, et al: Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress?: a meta- analysis of 20 phase 3 trials. Cancer 2007, 110(3):525-533. 19. Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in medicine 1998, 17(24):2815-2834. 20. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16. 21. Higgins JPT, Green S: Cochrane handbook for Systematic Reviews of intervention 4.2.6 [updated sep 2006]. The Cochrane Library Chichester, UK: John Wiley & Sons, Ltd; 2006, vol. Issue 4. 22. Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R: Interpreting measures of treatment effect in cancer clinical trials. The oncologist 2002, 7(3):181-187. 23. Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, Sperduti I, Carlini P, Terzoli E, Cognetti F, Giannarelli D: Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials. Lung Cancer 2008, 63(1):50-7. 24. Parmar MKB, Machin D: Survival analysis: a practical approach. Chichester (England): John Wiley; 1995. 25. Altman DG: Confidence intervals for the number needed to treat. BMJ (Clinical research ed 1998, 317(7168):1309-1312. 26. Brufsky A, Bondarenko I, Smirnov V, Hurvitz S, Perez E, Ponomarova O, Vynnychenko I, Swamy R, Mu H, Rivera R: RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. Cancer Res 2009, 69:42, (24_MeetingAbstracts). 27. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23(4):792-799. 28. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, et al: Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008, 26(24):3950-3957. 29. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline- pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20(12):2812-2823. 30. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Luck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, et al: Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008, 26(12):1980-1986. 31. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009, 101(23):1642-1649. 32. Lee JB, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee ES, Kim YH, Kim JS, Seo JH: Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs 2009, 29(1):182-8. 33. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D: Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 122(1):1-7. 34. Miles DW, Romieu G, Dieras V, Chen D, Duenne A, Robert N: Meta-analysis of patients (PTS) 65 years from three Randomized trials of Bevacizumab (BV) and first-line Chemotherapy as treatment for Metastatic Breast Cancer (MBC). European Society for Medical Oncology (ESMO): 2010; Milan (ITALY) Annals of Oncology; 2010, viii96-viii121, (#278PD). 35. Miles DW, Romieu G, Dieras V, Chen D, Duenne A, O’Shaughnessy J: Meta- analysis of patients (PTS) previously treated with Taxanes from three Randomized trials of Bevacizumab (BV) and first-line Chemotherapy as treatment for Metastatic Breast Cancer (MBC). European Society for Medical Oncology (ESMO): 2010; Milan (ITALY) Annals of Oncology; 2010, viii96-viii121, (#279PD). 36. Straus SE: Individualizing treatment decisions. The likelihood of being helped or harmed. Evaluation & the health professions 2002, 25(2):210-224. 37. Barrios C, Liu M, Lee S, Vanlemmens L, Ferrero J, Tabei T, Pivot X, Iwata H, Aogi K, Brickman M, et al: Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative